Business
New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new data from its Phase 2a Human Challenge Study of EDP-938 is being presented as a late-breaker oral presentation today at IDWeek™ 2019 in Washington, D.C. EDP-938 is Enanta’s lead N-protein inhibitor being developed for the treatment of RSV infection.\n\n\nToday’s late-breaking oral presentation will include data demonstrating that in the RSV Challenge study EDP-938 administered once or twice daily achieved highly statistically significant reductions (p","length":855,"tagName":"div"}]